BioNTech SE Sponsored ADR (BNTX) closed the last trading session at $112.76, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which ...

BioNTech SE ADR closed $8.64 short of its 52-week high ($131.49), which the company achieved on September 17th.

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

BioNTech (BNTX) is presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA therapeutics, immunomodulators, and ...

Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches ...

Unfortunately, as the pandemic eased, the Pfizer stock began to suffer. BioNTech was anticipated to enjoy the same Biden boost as headline vaccine producer Pfizer, thanks to the state of the ...

I made four predictions about the stock market in 2024. The Fed indeed cut rates in Q4, but stocks didn't jump as much as I ...

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

BioNTech (NASDAQ:BNTX) announced Friday two separate agreements worth more than $1B with the National Institutes of Health (NIH) and the University of Pennsylvania to resolve royalty and other ...